All Stories

  1. Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells
  2. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents
  3. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients
  4. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation
  5. Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate
  6. Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment
  7. Galcetin - 3 and Cardiorenal Disease
  8. Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study
  9. Tenofovir and kidney transplantation: case report
  10. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies
  11. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients
  12. Vitamin D and cardiovascular prevention
  13. MP374INFLAMMATION BUT NOT DERANGED MINERAL METABOLISM MAY EXPLAIN THE PROGRESSION OF CORONARY ARTERY CALCIFICATION IN CKD PATIENTS NOT ON DIALYSIS
  14. SP327THE ROLE OF PHOSPHORUS, PTH, FGF-23, KLOTHO AND VITAMIN D ON HEMOGLOBIN LEVELS OF PATIENTS WITH CKD
  15. Vitamin D in patients with chronic kidney disease: a position statement of the Working Group “Trace Elements and Mineral Metabolism” of the Italian Society of Nephrology
  16. Simultaneous abdominal wall defect repair and Tenckhoff catheter placement in candidates for peritoneal dialysis
  17. Multimodal treatment of calcific uraemic arteriolopathy (calciphylaxis): a case series
  18. Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease
  19. Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment
  20. Crosstalk between intestine and kidney. Revival of an ancient link
  21. FP429FIBROBLAST GROWTH FACTOR-23 AND PARATHYROID HORMONE PREDICT THE EXTENT OF AORTIC VALVE CALCIFICATIONS IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS
  22. SP635CINACALCET BUT NOT VITAMIN D USE MODULATES THE SURVIVAL BENEFIT ASSOCIATED WITH SEVELAMER IN THE INDEPENDENT STUDY
  23. Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract
  24. Chronic kidney disease and cardiovascular complications
  25. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: A randomized clinical trial
  26. Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease
  27. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study
  28. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study
  29. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease
  30. Hemodynamic and Tubular Changes Induced by Contrast Media
  31. The Choice of the Iodinated Radiographic Contrast Media to Prevent Contrast-Induced Nephropathy
  32. Impact of BMI on Cardiovascular Events, Renal Function, and Coronary Artery Calcification
  33. Sevelamer Is Cost-Saving vs. Calcium Carbonate in Non-Dialysis-Dependent CKD Patients in Italy: A Patient-Level Cost-Effectiveness Analysis of the INDEPENDENT Study
  34. Prevention of Contrast-Induced Nephropathy through a Knowledge of Its Pathogenesis and Risk Factors
  35. Serum fetuin-A and recurrent urolithiasis in young adults
  36. Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial
  37. Phosphate binders in moderate chronic kidney disease: where do we stand?
  38. Progression of cardiac valve calcification and decline of renal function in CKD patients
  39. Coronary Artery Calcification and Outcomes in Diabetic Patients with and without Chronic Kidney Disease
  40. Arterial Stiffness, Pulse Wave Analyses: What Can’t Blood Pressure Tell you in Chronic Kidney Disease
  41. Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study
  42. Arterial Stiffness, Pulse Wave Analyses: What Can't Blood Pressure Tell you in Chronic Kidney Disease
  43. Pulse Pressure and Presence of Coronary Artery Calcification
  44. Mortality in Kidney Disease Patients Treated with Phosphate Binders: A Randomized Study
  45. Awareness of kidney diseases in general population and in high school students. Italian report for World Kidney Days 2010-2011
  46. Dialysate bath and QTc interval in patients on chronic maintenance hemodialysis: pilot study of single dialysis effects
  47. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis
  48. Variability of pulse wave velocity and mortality in chronic hemodialysis patients
  49. Coronary artery calcification and cardiovascular mortality in predialysis patients
  50. Clinical Significance of FGF-23 in Patients with CKD
  51. The Phosphorus and the Vascular Calcification in ESRD between Old Adventures and New Horizons
  52. Coronary Artery Calcification Progression Is Associated with Arterial Stiffness and Cardiac Repolarization Deterioration in Hemodialysis Patients
  53. Risk for chronic kidney disease in high school students: Italian report for World Kidney Day 2008-2009
  54. Diagnostic Workup for Disorders of Bone and Mineral Metabolism in Patients with Chronic Kidney Disease in the Era of KDIGO Guidelines
  55. Phosphorus and coronary calcification in predialysis patients
  56. Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin
  57. Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients
  58. Awareness of Hypertension and Proteinuria in Randomly Selected Patients in 11 Italian Cities. A 2005 Report of the National Kidney Foundation of Italy
  59. Pulse Pressure and Presence of Coronary Artery Calcification
  60. Inhibition of Urea Tubular Reabsorption by PGE1 Infusion in Man
  61. Torasemide, a New Loop Diuretic, in Patients with Chronic Renal Failure
  62. Randomised Prospective Study on Renal Effects of Two Different Contrast Media in Humans: Protective Role of a Calcium Channel Blocker
  63. Effects of Furosemide Therapy on Free-Water Excretion in Uremic Patients
  64. Treatment of Massive Hemorrhage after Renal Biopsy with Percutaneous Arterial Obliteration
  65. Treatment of Severe Renovascular Hypertension by Percutaneous Transluminal Renal Angioplasty in Patients with Solitary Functioning Kidney
  66. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer
  67. Progression of Coronary Artery Calcification in Predialysis Patients
  68. Mesangial hypercellularity predicts antiproteinuric response to dual blockade of RAS in primary glomerulonephritis
  69. Treatment of Hypertension in Italian Nephrology Out-patient Clinics: The THIN Study
  70. Kaposi's sarcoma occurring in a young black man after kidney transplantation
  71. Matrix GLA Protein Gene Polymorphisms: Clinical Correlates and Cardiovascular Mortality in Chronic Kidney Disease Patients
  72. Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy
  73. Combined use of enalapril and losartan to reduce proteinuria: A question of safety: In reply
  74. Combined use of enalapril and losartan to reduce proteinuria: A question of safety
  75. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
  76. Effect of posture on sodium excretion and diuretic efficacy in nephrotic patients
  77. Endothelin-1 released by vascular smooth muscle cells enhances vascular responsiveness of rat mesenteric arterial bed exposed to high perfusion flow
  78. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
  79. Diuretics in Renal Failure
  80. Effects of Water Hardness on Urinary Risk Factors for Kidney Stones in Patients with Idiopathic Nephrolithiasis
  81. Comparison of losartan and amlodipine in renally impaired hypertensive patients
  82. Vasomotor nephropathy in the elderly
  83. Gross hematuria of uncommon origin: The nutcracker syndrome
  84. I018 Endothelin-1 released by vascular smooth muscle cells (VSMCS) enhances vascular responsiveness of rat mesenteric arterial bed (MA) exposed to high perfusion flow (HPF)
  85. Antiproteinuric effect of Losartan in patients with chronic renal diseases
  86. Some sodium, potassium and water changes in the elderly and their treatment
  87. Role of Loop Diuretics in Chronic Renal Failure
  88. Extra-natriuretic effects of atrial peptide in humans
  89. Role of inhibition of atrial natriuretic factor release in the down-regulation of salt excretion
  90. Renal functional reserve: Its significance in normal and salt depletion conditions
  91. Vascular Hypertrophy, Renin and Blood Pressure in the Young Spontaneously Hypertensive Rat
  92. Increased sensitivity to noradrenaline in glucocorticoid-treated rats: the effects of indomethacin and desipramine
  93. Absence of Acute Nephrotoxicity with Low Doses of Cyclosporin: Experimental Study in the Rat
  94. Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects
  95. Vascular hypertrophy and the renin-angiotensin system in the three-week-old spontaneously hypertensive rat
  96. Total or partial percutaneous renal ablation in the treatment of renovascular hypertension: radiological and clinical aspects
  97. Dexamethasone therapy selectively increases the sensitivity to noradrenaline of the rat mesenteric circulation
  98. Torasemide, a Loop Diuretic, Useful in Correcting ECF Volume Expansion in Patients with Chronic Renal Failure
  99. Effects of Uremia, Acetate and Bicarbonate Dialysis on Beta-Adrenergic Responsiveness as Assessed by Epinephrine-Stimulated Adenylate Cyclase
  100. Percutaneous renal embolisation in renovascular hypertension
  101. Hypertension in Pregnancy
  102. Renal handling of urea in subjects with persistent azotemia and normal renal function
  103. Antihypertensive Mechanisms of Muzolimine
  104. Effects of Enalapril on Water and Salt Balance and Renal Hemodynamics
  105. Treatment of Chronic Hypertension in Pregnancy
  106. Effects of pregnancy on glomerular dynamics: Micropuncture study in the rat
  107. Muzolimine: a new high-ceiling diuretic suitable for patients with advanced renal disease.
  108. Echocardiographic Detection of Cardiac effects of Arterio-Venous Dialysis Fistula
  109. Relationship between serum albumin concentration and tubular reabsorption of glucose in renal disease
  110. Effects of Hypertension on Renal Function in Pregnant Rats
  111. Post-Traumatic Acute Renal Failure: Clinical Experience after the Earthquake in Southern Italy